FATE
Fate Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
Revenue Plunges
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About FATE
Fate Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing programmed cellular immunotherapies for the treatment of cancer diseases
Pharmaceutical
04/27/2007
10/01/2013
NASDAQ Stock Exchange
181
12-31
Common stock
12278 Scripps Summit Drive, San Diego, California 92131
--
Fate Therapeutics, Inc., merged in Delaware on April 27, 2007, is a clinical staging biopharmaceutical company dedicated to the exploration and development of adult stem cell therapy modulators for the treatment of rare diseases, including some malignant hematological diseases, lysosomal storage disorder and muscular dystrophy. Some of the new approaches used by Fate take existing therapeutic models, including small molecules and therapeutic proteins, and target good biological mechanisms to enhance the efficacy of adult stem cells.
Company Financials
EPS
FATE has released its 2024 Q4 earnings. EPS was reported at -0.44, versus the expected -0.42, missing expectations. The chart below visualizes how FATE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FATE has released its 2024 Q4 earnings report, with revenue of 1.86M, reflecting a YoY change of 10.98%, and net profit of -52.15M, showing a YoY change of -18.20%. The Sankey diagram below clearly presents FATE’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
